Company intelligence / Profile preview

AmniSure International

Boston, Massachusetts, United Statesprnewswire.com ↗

Ownership: Private
Development stage: Other

Overview

The company developed and commercialized the AmniSure® rapid ROM test, a point-of-care diagnostic device that provides quick and reliable results for detecting rupture of fetal membranes in pregnant women. The test is widely used in clinical settings to help manage pregnancy complications related to premature membrane rupture. It was acquired by Qiagen in 2012 and continues to be marketed under their portfolio. The product generated an estimated $12 million in sales over part of 2012, with expectations for $24 million annualized revenue post-acquisition [6].

Therapeutic areas: Women's Health
Modalities: Device
Industry: Protein Biomarker Diagnostics

Beyond the preview

Go deeper on AmniSure International.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AmniSure International.

Explore the full profile